You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202181 - 202190 of 207728 results
  1. VACCINE FOR LEISHMANIASIS

    SBC: Corpixa Corp.            Topic: N/A

    N/A

    SBIR Phase I 1996 Department of Health and Human Services
  2. Vaccine for Mycobacterium Tuberculosis

    SBC: Corpixa Corp.            Topic: N/A

    The goal of this investigation is to develop the invasin gene as a vaccine against M. tuberculosishuman host. Up to the present time, the only known and generally accepted vaccine-BCG-is a living athas shown variable efficacy in the countries where it has been used. Although efforts by other invesof obtaining non-viable vaccine have not proved successful, the concept of a new candidate vaccine cpr ...

    SBIR Phase I 1995 Department of Health and Human Services
  3. VACCINE/HEALTH ECONOMICS LINEAR PROGRAMMING SOFTWARE

    SBC: MEDICAL DECISION ASSOCIATES, INC.            Topic: N/A

    N/A

    SBIR Phase I 1998 Department of Health and Human Services
  4. VACCINE POTENTIAL OF TOXOPLASMA GONDII RECOMBINANT P3

    SBC: Paravax Inc.            Topic: N/A

    P30, THE MAJOR SURFACE ANTIGEN OF THE TOXOPLASMA GONDII TACHYZOITE STAGE, HAS BEEN ISOLATED FROM THE PARASITE AND SHOWN TO PROTECT MICE FROM A VIRULENT T. GONDII CHALLENGE. THE CDNA ENCODING P30 HAD BEEN CLONED AND EXPRESSED IN E. COLI, PRODUCING RECOMBINANT PROTEIN THAT WAS POORLY RECOGNIZED BY ANTIBODY TO NATIVE PROTEIN. THE SPECIFIC AIM OF THIS PROJECT IS TO DEMONSTRATE THAT RECOMBINANT P30 CAN ...

    SBIR Phase II 1993 Department of Health and Human Services
  5. VACCINE POTENTIAL OF TOXOPLASMA GONDII RECOMBINANT P3

    SBC: Paravax Inc.            Topic: N/A

    N/A

    SBIR Phase I 1991 Department of Health and Human Services
  6. VACCINES DESIGNED FROM ANALYSIS OF RECENT HIV INFECTIONS

    SBC: VAXGEN, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): An effective vaccine is the only practical way to halt the AIDS epidemic. The greatest challenge in developing an effective HIV vaccine is antigenic variation. Therefore, the present project aim is to enhance the understanding of antigenic variation by characterizing intra-subtype sequence variation among gpl20 genes from incident (new) infections, and identi ...

    SBIR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  7. Vaccines Designed From Analysis of Recent HIV Infections

    SBC: VAXGEN, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): An effective vaccine is the only practical way to halt the AIDS epidemic. The greatest challenge in developing an effective HIV vaccine is antigenic variation. Therefore, the present project aim is to enhance the understanding of antigenic variation by characterizing intra-subtype sequence variation among gpl20 genes from incident (new) infections, and identi ...

    SBIR Phase II 2003 Department of Health and Human ServicesNational Institutes of Health
  8. Vaccines for Eastern and Western Equine Encephalitis Viruses

    SBC: MAXYGEN, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Venezuelan, eastern, and western equine encephalitis viruses (VEEV, EEEV, WEEV respectively) are arthropod-borne alphaviruses that cause periodic epizootics in the Americas. No licensed vaccines exist for these pathogens, and the experimental vaccines used under Investigational New Drug status suffer from high reactogenicity or poor immunogenicity. Vaccines aga ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Vaccine Strategies for Candidal Infections

    SBC: NOVADIGM THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Candida is a fungus that is among the most common causes of infections in hospitalized patients in the United States and worldwide. Candida spp. are one of the most common microbes that infect the blood and urine of hospitalized patients. The cost associated with Candida blood infections alone exceeds at least $1 billion per year in the US. Even with therapy, 4 ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Vaccine Strategies for Candidal Infections

    SBC: NOVADIGM THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Candida is a fungus that is among the most common causes of infections in hospitalized patients in the United States and worldwide. Candida spp. are one of the most common microbes that infect the blood and urine of hospitalized patients. The cost associated with Candida blood infections alone exceeds at least $1 billion per year in the US. Even with therapy, 4 ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government